First National Bank & Trust Co. of Newtown Has $1.29 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

First National Bank & Trust Co. of Newtown decreased its stake in Abbott Laboratories (NYSE:ABT) by 11.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,398 shares of the healthcare product maker’s stock after selling 1,500 shares during the period. First National Bank & Trust Co. of Newtown’s holdings in Abbott Laboratories were worth $1,289,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in ABT. Allspring Global Investments Holdings LLC grew its stake in Abbott Laboratories by 17.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 268,538 shares of the healthcare product maker’s stock worth $30,616,000 after purchasing an additional 40,783 shares during the period. Trilogy Capital Inc. grew its stake in Abbott Laboratories by 5.6% during the third quarter. Trilogy Capital Inc. now owns 2,503 shares of the healthcare product maker’s stock worth $285,000 after purchasing an additional 132 shares during the period. Copeland Capital Management LLC acquired a new stake in Abbott Laboratories during the third quarter worth approximately $142,000. My Legacy Advisors LLC grew its stake in Abbott Laboratories by 2.3% during the third quarter. My Legacy Advisors LLC now owns 4,180 shares of the healthcare product maker’s stock worth $477,000 after purchasing an additional 92 shares during the period. Finally, Symphony Financial Ltd. Co. grew its stake in Abbott Laboratories by 11.2% during the third quarter. Symphony Financial Ltd. Co. now owns 8,571 shares of the healthcare product maker’s stock worth $964,000 after purchasing an additional 863 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares in the company, valued at approximately $16,152,064.50. This represents a 15.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.47% of the company’s stock.

Abbott Laboratories Stock Up 1.5 %

Shares of NYSE:ABT opened at $132.18 on Thursday. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $132.65. The company has a market cap of $229.26 billion, a PE ratio of 17.28, a P/E/G ratio of 2.44 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The stock’s 50-day moving average is $119.93 and its 200 day moving average is $116.53.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. During the same quarter in the previous year, the business earned $1.19 EPS. Abbott Laboratories’s revenue was up 7.2% compared to the same quarter last year. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th were issued a dividend of $0.59 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. Abbott Laboratories’s dividend payout ratio is 30.85%.

Wall Street Analyst Weigh In

ABT has been the topic of several recent research reports. StockNews.com lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Argus upgraded Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. Barclays reiterated an “overweight” rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Evercore ISI increased their price target on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a report on Thursday, January 2nd. Finally, Stifel Nicolaus increased their price target on Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.06.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.